Short sellers have largely abandoned GILD ahead of today's earnings. Just 1.73% of the float is sold short, up slightly from March lows but still among the lowest in large-cap biotech.
Short interest stands at 21.5 million shares, or 1.73% of free float. Days to cover is 3.2 sessions. The position rose 17% over the past month but remains thin by sector standards. Cost to borrow jumped 47% in 30 days to 0.54%, though the rate itself is still negligible. Utilisation sits at just 0.37%, down from 0.52% a week ago. Shares to borrow are plentiful. The ORTEX short score is 32, indicating neutral positioning.
The put/call ratio is 0.58, elevated versus the 20-day mean of 0.54. The PCR z-score is 0.85, suggesting modest put bias. Over the past month, PCR has declined from March highs near 0.78 back toward the April lows near 0.48. The recent uptick coincides with the stock's 3.5% weekly decline. Traders are leaning defensive into the print, but sentiment is not extreme.
Analyst data is unavailable in the current snapshot. Wall Street consensus and target price ranges are not provided.
Gilead last reported on February 10, 2026, after market close. The announcement came the same day as the print. Prior prints in the fiscal calendar also clustered around mid-quarter reporting windows. Historical price reactions are not detailed in the snapshot, but the stock closed today at $133.64, down 2.7% over the past month.
No active ORTEX Alpha signals are present. Recent triggered signals are also absent.
See the live data behind this article on ORTEX.
Open GILD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
